



Canadian Cardiometabolic Risk Management Postcard

Edit this text for contact info, address etc


(DELETE THIS BOX & PLACE LOGO HERE)

Helping people with serious mental illness live healthier and longer

I am asking for your support to have well-planned physical health monitoring.

LET'S WORK TOGETHER:

- My mental health team
- My family MD
 - My family
 - and Me



I often miss out on monitoring of my risks for obesity, diabetes and heart disease.

I want to be clear on who is monitoring my physical health

I need information on healthy:

- Medication options
- Diet Choices
- Activity Levels

Poor physical health contributes to 15-20 years loss of life

I may have higher rates of:

- Inactivity
- Smoking
- Poor eating habits

I am **2-3 times more likely** to develop diabetes

I am **2-3 times more likely** to suffer a heart attack or a stroke

Please call: _____

REGULAR PHYSICAL HEALTH CHECK-UPS MAKE A DIFFERENCE!

The Canadian Cardiometabolic Risk Management Resource was developed for doctors, nurses, and the mental health team.

It offers guidance on physical health monitoring to help people with serious mental illness avoid complications like diabetes, heart disease and stroke.




You can download the Canadian Cardiometabolic Risk Management Resource here: <http://eenet.ca/the-early-intervention-in-psychosis-for-youth-community-of-interest/>

Adapted for use with permission from the Lester Resource Shiers D et al 2014

Cardiometabolic Risk Management | Antipsychotics (Mood Stabilizers & Antidepressants*)

*Despite less available evidence, similar principles apply to these medication classes



Monitoring: How Often and What to Do

Applies to patients prescribed antipsychotics and metabolically active mood stabilizers and antidepressants
Frequency: As a minimum review those prescribed a new agent at baseline and at least once after 3 months. Weight should be assessed monthly in the first 3 months of taking a new antipsychotic as rapid weight gain may predict severe weight gain in the longer term. Subsequent review should take place annually unless an abnormality of physical health emerges, which should then prompt appropriate action and/or continuing review at least every 3 months.

	Baseline	4 weeks	8 weeks	12 weeks	Quarterly	Annually	History:
Personal/FHx	X					X	Ask about family history (diabetes, obesity) CV/D in first degree relatives ≥ 60 yrs, gestational diabetes, Note ethnicity.
Lifestyle Review ¹	X	X	X	X	X	X	
Weight/WC	X	X	X	X	X	X	
BP	X			X		X	
FPG/HbA1c	X			X		X	
Lipid Profile ²	X			X		X	

¹Smoking, diet, and physical activity ²If fasting lipid profile cannot be obtained, a non-fasting sample is satisfactory
Derived from consensus guidelines 2004, J clin. psych 65:2

Investigations
Fasting estimates of plasma glucose (FPG), HbA1c, and lipids (total cholesterol, non-HDL, HDL, triglycerides). If fasting samples are impractical, then non-fasting samples are satisfactory for most measurements except for triglycerides.

Review of Antipsychotic Medication
Choose lower metabolic liability medication first-line when possible. Response in first episode psychosis is robust independent of agent. Changing or discontinuing antipsychotic requires careful clinical judgment, balancing metabolic benefits against relapse risk. Ideally psychiatrist supervised. Should be a priority if there is:
- Rapid weight gain (e.g. 5kg < 3 months) following antipsychotic initiation.
- Rapid development (< 3 months) of abnormal lipids, BP, or glucose.
The psychiatrist should consider whether the antipsychotic drug regimen has played a causative role in these abnormalities and, if so, whether an alternative regimen could be expected to offer less adverse effect.
If clinical judgment and patient preference support continuing with the same treatment then ensure appropriate further monitoring and clinical considerations.
Avoid antipsychotic polypharmacy when possible; Avoid off-label use of antipsychotics.

Specific Adjunctive Pharmacological Interventions
For mitigation of excess weight gain associated with antipsychotic use, the strongest evidence is for off-label use of Metformin and Topiramate (Mayan, 2010). Consider Metformin first due to better tolerability profile unless there is a co-morbid binge-eating disorder (McElroy, SI, 2009). Please be advised that off-label use requires documented informed consent. Discontinue if no sign of efficacy (continuing weight gain if used for weight loss or stabilization) after 3 months at therapeutic dose.
Metformin:
Weight Gain & Primary Prevention of Diabetes: Start 250 mg po BID, titrate every 1-2 weeks as clinically indicated and tolerated. Dose range 1750 mg - 2 Gm/day
Caution with renal or hepatic impairment. Avoid excessive alcohol use. Monitor for GI side effects. Monitor for B12 deficiency.
Topiramate:
Weight Gain: Start 125 mg po BID, titrate by 25-50 mg per day in divided doses every 1-2 weeks as tolerated to a maximum of 100 mg po BID.
Caution with renal or hepatic impairment. Avoid excessive alcohol use. Monitor for cognitive changes. Parosmia is common but generally well-tolerated.

DON'T JUST SCREEN: INTERVENE!

FOR ALL PATIENTS IN THE DANGER ZONE

The primary care provider and psychiatrist will work together to ensure appropriate monitoring and interventions are provided and communicated to avoid over or under monitoring. The primary care provider will usually lead on decisions to significantly change antipsychotic medicines.

The Le Royal | Ontario Shores
Mental Health - Care & Research | Centre for Mental Health Sciences
Santé mentale - Soins et recherche

The Ottawa Hospital | Etobicoke | Waypoint
Centre for Mental Health Sciences | Centre de Soins et Santé Mentale

camh Centre for Addiction and Mental Health
EPION
EARLY PSYCHOSIS INTERVENTION ONTARIO NETWORK

With thanks to the On Track FEP program for their collaboration
Adapted for use by the Ontario Metabolic Task Force.
With permission from Curtis J, Newell H, Samaras K. © HETI 2011; Shiers, D et al